Literature DB >> 9738835

The effects of increasing levels of quinolone resistance on in-vitro activity of four quinolones.

K S Thomson1, C C Sanders.   

Abstract

A panel of 266 clinically isolated Gram-positive cocci and Gram-negative bacilli with varying levels of resistance to ciprofloxacin were analysed for susceptibility to Du-6859a, ciprofloxacin, ofloxacin, temafloxacin and nalidixic acid. Staphylococci were divided into ciprofloxacin-susceptible, moderately resistant and highly resistant subgroups. Du-6859a was the most potent quinolone against all taxa. As ciprofloxacin resistance increased to high levels, MICs of all quinolones increased but Du-6859a MICs increased least, and ciprofloxacin MICs increased most. Less susceptible single-step mutants were selected from 80% of 15 representative clinical isolates exposed to ciprofloxacin, 71% of isolates exposed to temafloxacin, 67% of isolates exposed to Du-6859a and 53% of isolates exposed to ofloxacin. Du-6859a inhibited more mutants (67%) at a concentration of 1 mg/L than did the other quinolones (26-43%) at their susceptible breakpoints. Du-6859a was the most rapidly bactericidal quinolone in time-kill studies with Enterococcus faecalis and Enterococcus faecium. This study indicated that Du-6859a is more potent than the comparator quinolones, is less affected by the mechanisms responsible for high-level quinolone resistance and may be less likely to select resistant mutants if it has a susceptible breakpoint of 1 mg/L.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9738835     DOI: 10.1093/jac/42.2.179

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  7 in total

1.  Association of alterations in ParC and GyrA proteins with resistance of clinical isolates of Enterococcus faecium to nine different fluoroquinolones.

Authors:  S Brisse; A C Fluit; U Wagner; P Heisig; D Milatovic; J Verhoef; S Scheuring; K Köhrer; F J Schmitz
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

Review 2.  Ofloxacin otic solution: a review of its use in the management of ear infections.

Authors:  K L Simpson; A Markham
Journal:  Drugs       Date:  1999-09       Impact factor: 9.546

Review 3.  A critical review of the fluoroquinolones: focus on respiratory infections.

Authors:  George G Zhanel; Kelly Ennis; Lavern Vercaigne; Andrew Walkty; Alfred S Gin; John Embil; Heather Smith; Daryl J Hoban
Journal:  Drugs       Date:  2002       Impact factor: 9.546

4.  Not so simple cystitis: how should prescribers be supported to make informed decisions about the increasing prevalence of infections caused by drug-resistant bacteria?

Authors:  P Davey; D Steinke; T MacDonald; G Phillips; F Sullivan
Journal:  Br J Gen Pract       Date:  2000-02       Impact factor: 5.386

5.  Crystal structure of Streptococcus pneumoniae acyl carrier protein synthase: an essential enzyme in bacterial fatty acid biosynthesis.

Authors:  N Y Chirgadze; S L Briggs; K A McAllister; A S Fischl; G Zhao
Journal:  EMBO J       Date:  2000-10-16       Impact factor: 11.598

6.  Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance.

Authors:  J M Entenza; Y A Que; J Vouillamoz; M P Glauser; P Moreillon
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

Review 7.  A benefit-risk assessment of ofloxacin otic solution in ear infection.

Authors:  Talen K H Wai; Michael C F Tong
Journal:  Drug Saf       Date:  2003       Impact factor: 5.228

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.